|
Lithobid (Lithium carbonate)
|
|
Central nervous system agent
|
|
Antipsychotic agent
|
|
Major Depression, schizoffective disorder, apparent mixed bipola disorder in children, chemotherapy-induced neutropenia in children and patients with AIDS receiving zidovudine, manic episodes of manic-depressive illness, maintenance therapy of manic-depressive illness.
|
|
(Adults and children >12 years) Acute manic episodes: 1800mg/day in 2 divided doses. Long-term control: 900-1200mg/day in 2 divided doses.
|
|
Category D.
|
|
Hand tremor, thirst, nausea, Diarrhea, vomiting, drowsiness, muscular weakness, lack of coordination, frequent urination, coma, epileptiform Seizures, arrhythmias, Bradycardia, Tinnitus, renal toxicity, leukocytosis with WBC elevated neutrophil count, Goiter, pruritus
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
|
|
|